Abbott (NYSE:ABT) said it won approval from the Japanese Ministry of Health, Labor and Welfare for its next-generation Xience Prime coronary stent
The nod means the cobalt-chromium stent is "available in all of the major markets worldwide," according to a press releaase, including the U.S., Europe, China and India.